Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

IDBS and Genevant partnership aims to advance drug discoveries

Share this on social media:

IDBS, a provider of enterprise scientific informatics platforms has announced a new SaaS contract with Genevant Sciences Corporation, a leading biopharmaceutical company focused on the discovery and development of a broad range of RNA-based therapeutics across multiple modalities.

The arrangement will combine Genevant’s RNA therapeutic expertise with the R&D and discovery data management expertise of IDBS. This includes IDBS’ E-WorkBook Electronic Laboratory Notebook (ELN), designed to capture and manage critical data to increase laboratory efficiency and boost compliance by reducing errors and strengthening lab safety.

Christian Marcazzo, General Manager at IDBS said: 'We are delighted to win this high-profile contract with one of the first modality-agnostic RNA therapeutics companies. Our work with Genevant will focus on research and development of innovative new medicines and potential cures. On our cloud platform, Genevant is empowered to solely focus on their science and future therapeutics for improving patient outcomes.'

The E-WorkBook Cloud platform will run on the Amazon Web Services (AWS) Cloud, providing Genevant, including IDBS’ cloud-based ELN, with the tools to improve throughput and the number of studies it can achieve, ultimately leading to more efficient, productive researchers. With the support and partnership of AWS, The E-WorkBook Cloud puts Genevant in the best position to accelerate it's business’ scientific innovation and bring new therapeutics to market for patients.

Company: